ABSTRACT
Background Little is known about the performance of the Roche novel severe acute respiratory syndrome coronavirus 2 antibody (anti-SARS-CoV-2) assay. We provide an extensive evaluation of this fully automated assay on the Cobas e801/e602 immunoassay analysers.
Methods We assessed the linearity, precision, and throughput of the Roche anti-SARS-CoV-2 assay. Sensitivity was calculated from 349 SARS-CoV-2 polymerase chain reaction (PCR) positive samples; specificity was determined from 714 coronavirus disease 2019 (COVID-19)-naive samples. We examined cross-reactivity against other antibody positive samples (syphilis, RF, ANA, ds-DNA, influenza, dengue, HBV, HCV) and the anti-SARS-CoV-2 kinetics.
Results The assay cut-off index (COI) was linear up to 90.7. The inter-assay precision was 2.9% for a negative control (COI=0.1) and 5.1% for a positive control (COI=3.0). Assay time is 18min and results are available 1 minute later; throughput for 300 samples was 76 minutes. No cross-reactivity was observed with other antibody positive samples; specificity was 100%. The assay has a sensitivity of 97.1% 14 days after PCR positivity (POS) and 100% at ≥21 days POS; 48.2% of cases had anti-SARS-CoV-2 within 6 days POS. In 11 subjects in whom serum was available prior to a positive antibody signal (COI ≥1.0) the interval between the last negative and first positive COI (time to “sero-conversion”) on average is 3 days (range 1-6 days) and 4 more days (range 1-7) for the anti-SARS-CoV-2 to plateau.
Conclusion The Roche anti-SARS-CoV-2 assay shows excellent performance with minimal cross-reactivity from other viral and confounding antibodies. Antibody development and sero-conversion appears quite early.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
CHANGI GENERAL HOSPITAL INSTITUTIONAL REVIEW BOARD
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure: All authors have nothing to disclose.
Data Availability
NA
ABBREVIATIONS
- SARS-CoV-2
- Novel severe acute respiratory syndrome coronavirus 2
- COVID-19
- Coronavirus disease 2019
- Anti-SARS-CoV-2
- SARS-CoV-2 antibody
- FDA
- Food and Drug Administration
- HCV
- Hepatitis C
- HBV
- Hepatitis B
- RF
- Rheumatoid factor
- HCWs
- Health care workers
- COI
- Cut-off index
- PCR
- Polymerase chain reaction
- CV
- Inter-assay precision
- PPA
- Positive percentage agreement
- NPA
- Negative percentage agreement
- POS
- Post positive PCR
- PPV
- Positive predictive value
- NPV
- Negative predictive value
- CDC
- Centers for Disease Control and Prevention
- PPE
- Personal protective equipment
- ANA
- anti-nuclear antibody
- Anti-ds-DNA
- double-stranded DNA antibody
